Anesthesia for Vascular Surgery
| dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
| dc.contributor.author | SIMõES, C. M. | |
| dc.date.accessioned | 2023-12-04T19:42:04Z | |
| dc.date.available | 2023-12-04T19:42:04Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Anesthesia for vascular procedures in cancer patients can be challenging. In this chapter, we discuss some important aspects in preoperative evaluation and anesthesia planning, including risk stratification, medications, and also other patient potential risks. Onco-anesthesia has some specific aspects and should be considered an emerging subspecialty with critical competencies to be developed. Venous access, hemodynamic monitoring, blood and fluid management, analgesia, and also enhanced recovery bundles must be considered for all patients. Also, anesthesia technique may be an important factor to be studied. Postoperative care is also specific, and we must consider some situations more frequent in cancer patients-that will be discussed as analgesia and its adverse effects-that may be present and should be prevented. © Springer Nature Switzerland AG 2022. | |
| dc.identifier.citation | Simões, C. M.. Anesthesia for Vascular Surgery. In: . Vascular Surgery in Oncology: SPRINGER INTERNATIONAL PUBLISHING, 2022. p.331-343. | |
| dc.identifier.doi | 10.1007/978-3-030-97687-3_9 | |
| dc.identifier.isbn | 978-303097687-3; 978-303097686-6 | |
| dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/57255 | |
| dc.language.iso | eng | |
| dc.publisher | SPRINGER INTERNATIONAL PUBLISHING | |
| dc.relation.ispartof | Vascular Surgery in Oncology | |
| dc.rights | restrictedAccess | |
| dc.rights.holder | Copyright SPRINGER INTERNATIONAL PUBLISHING | |
| dc.subject | Anesthesia | |
| dc.subject | Postoperative care | |
| dc.subject | Preoperative care | |
| dc.subject | Risk stratification | |
| dc.subject | Venous access | |
| dc.title | Anesthesia for Vascular Surgery | |
| dc.type | bookPart | |
| dc.type.category | book chapter | |
| dc.type.version | publishedVersion | |
| dspace.entity.type | Publication | |
| hcfmusp.citation.scopus | 0 | |
| hcfmusp.contributor.author-fmusphc | CLAUDIA MARQUEZ SIMOES | |
| hcfmusp.description.beginpage | 331 | |
| hcfmusp.description.endpage | 343 | |
| hcfmusp.origem | Scopus | |
| hcfmusp.origem.scopus | 2-s2.0-85158996038 | |
| hcfmusp.relation.reference | Gomez-Henao P.A., Carreno-Duenas J.A., Cardiovascular pre-anesthesia evaluation in oncological surgery, Colomb J Anesthesiol, 44, 1, pp. 17-22, (2016) | |
| hcfmusp.relation.reference | Velasco A., Reyes E., Hage F.G., Guidelines in review: Comparison of the 2014 ACC/AHA guidelines on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery and the 2014 ESC/ESA guidelines on noncardiac surgery: Cardiovascular assessment and management, J Nucl Cardiol, 24, pp. 165-170, (2017) | |
| hcfmusp.relation.reference | Abouleish A.E., Leib M.L., Cohen N.H., ASA provides examples to each ASA physical status class, ASA Monit, 79, 6, pp. 38-49, (2015) | |
| hcfmusp.relation.reference | Davenport D.L., Bowe E.A., Henderson W.G., Khuri S.F., Mentzer R.M., National Surgical Quality Improvement Program (NSQIP) risk factors can be used to validate American Society of Anesthesiologists Physical Status Classification (ASA PS) levels, Ann Surg, 243, 5, pp. 636-641, (2006) | |
| hcfmusp.relation.reference | Enioutina E.Y., Job K.M., Sherwin C.M.T., Spotlight commentary: Why we need to pay attention to toxicity associated with herbal medicines, Br J Clin Pharmacol, 86, 9, pp. 1793-1794, (2020) | |
| hcfmusp.relation.reference | Wang C.-Z., Moss J., Yuan C.-S., Commonly used dietary supplements on coagulation function during surgery, Medicines, 2, 3, pp. 157-185, (2015) | |
| hcfmusp.relation.reference | Garg R., Anesthesiologists, anesthetics, and cancer metastasis, J Anaesthesiol Clin Pharmacol, 30, 2, pp. 174-176, (2014) | |
| hcfmusp.relation.reference | Ben-Eliyahu S., Page G.G., Schleifer S.J., Stress, NK cells, and cancer: Still a promissory note, Brain Behav Immun, 21, 7, pp. 881-887, (2007) | |
| hcfmusp.relation.reference | Sessler D.I., Riedel B., Anesthesia and cancer recurrence: Context for divergent study outcomes, Anesthesiology, 130, 1, pp. 3-5, (2019) | |
| hcfmusp.relation.reference | Miao Y., Zhang Y., Wan H., Chen L., Wang F., GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells, Biomed Pharmacother, 64, 9, pp. 583-588, (2010) | |
| hcfmusp.relation.reference | Deegan C.A., Murray D., Doran P., Moriarty D.C., Sessler D.I., Mascha E., Et al., Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery, Reg Anesth Pain Med, 35, 6, pp. 490-495, (2010) | |
| hcfmusp.relation.reference | Ashrafizadeh M., Ahmadi Z., Farkhondeh T., Samarghandian S., Anti-tumor activity of propofol:A focus on microRNAs, Curr Cancer Drug Targets, 20, 2, pp. 104-114, (2020) | |
| hcfmusp.relation.reference | Stollings L.M., Jia L.-J., Tang P., Dou H., Lu B., Xu Y., Immune modulation by volatile anesthetics, Anesthesiology, 125, 2, pp. 399-411, (2016) | |
| hcfmusp.relation.reference | Grandhi R.K., Lee S., Abd-Elsayed A., Does opioid use cause angiogenesis and metastasis?, Pain Med, 18, 1, pp. 140-151, (2017) | |
| hcfmusp.relation.reference | Al-Hashimi M., Scott S.W.M., Thompson J.P., Lambert D.G., Opioids and immune modulation:More questions than answers, Br J Anaesth, 111, 1, pp. 80-88, (2013) | |
| hcfmusp.relation.reference | Chia P.A., Cannesson M., Bui C.C.M., Opioid free anesthesia: Feasible?, Curr Opin Anesthesiol, 33, 4, pp. 512-517, (2020) | |
| hcfmusp.relation.reference | Afonso A.M., Gottumukkala V., Enhanced surgical recovery programs in cancer care, ASA Monit, 82, 7, pp. 16-18, (2018) | |
| hcfmusp.relation.reference | Colditz G.A., De Jong W., Emmons K., Hunter D.J., Mueller N., Sorensen G., Harvard report on cancer prevention volume 2: Prevention of human cancer, Cancer Causes Control, 8, pp. S1-S3, (1997) | |
| hcfmusp.relation.reference | Grundy A., Poirier A.E., Khandwala F., Grevers X., Friedenreich C.M., Brenner D.R., Cancer incidence attributable to lifestyle and environmental factors in Alberta in 2012: Summary of results, CMAJ Open, 5, 3, pp. E540-E545, (2017) | |
| hcfmusp.relation.reference | Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J., Selected major risk factors and global and regional burden of disease, Lancet, 360, 9343, pp. 1347-1360, (2002) | |
| hcfmusp.relation.reference | Zerati A.E., Figueredo T.R., de Moraes R.D., da Cruz A.M., da Motta-Leal Filho J.M., Freire M.P., Wolosker N., de Luccia N., Risk factors for infectious and noninfectious complications of totally implantable venous catheters in cancer patients, J Vasc Surg Venous Lymphat Disord, 4, 2, pp. 200-205, (2016) | |
| hcfmusp.relation.reference | Zerati A.E., Wolosker N., de Luccia N., Puech-Leao P., Cateteres venosos totalmente implantáveis:Histórico, técnica de implante e complicações, J Vasc Bras, 16, 2, pp. 128-139, (2017) | |
| hcfmusp.relation.reference | Wolosker N., Yazbek G., Nishinari K., Malavolta L.C., Munia M.A., Langer M., Zerati A.E., Totally implantable venous catheters for chemotherapy: Experience in 500 patients, Sao Paulo Med J, 122, 4, pp. 147-151, (2004) | |
| hcfmusp.relation.reference | Nishinari K., Wolosker N., Yazbek G., Zerati A.E., Nishimoto I.N., Venous reconstructions in lower limbs associated with resection of malignancies, J Vasc Surg, 44, 5, pp. 1046-1050, (2006) | |
| hcfmusp.relation.reference | Nishinari K., Wolosker N., Yazbek G., Zerati A.E., Nishimoto I.N., Puech-Leao P., Arterial reconstructions associated with the resection of malignant tumors, Clinics, 61, 4, pp. 339-344, (2006) | |
| hcfmusp.relation.reference | Tomaselli G.F., Mahaffey K.W., Cuker A., Et al., 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways, J Am Coll Cardiol, 70, pp. 3042-3067, (2017) | |
| hcfmusp.relation.reference | Scaglione F., New oral anticoagulants: Comparative pharmacology with vitamin K antagonists, Clin Pharmacokinet, 52, 2, pp. 69-82, (2013) | |
| hcfmusp.relation.reference | Chan K.E., Giugliano R.P., Patel M.R., Abramson S., Jardine M., Zhao S., Perkovic V., Maddux F.W., Piccini J.P., Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF, J Am Coll Cardiol, 67, 24, pp. 2888-2899, (2016) | |
| hcfmusp.relation.reference | Ross B., Miller M.A., Ditch K., Tran M., Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: A case series, J Med Toxicol, 10, pp. 223-228, (2014) | |
| hcfmusp.relation.reference | Dager W.E., Gosselin R.C., Roberts A.J., Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity, Crit Care Med, 41, pp. e42-e46, (2013) | |
| hcfmusp.relation.reference | Dumkow L.E., Voss J.R., Peters M., Jennings D.L., Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma, Am J Health Syst Pharm, 69, pp. 1646-1650, (2012) | |
| hcfmusp.scopus.lastupdate | 2024-04-12 | |
| relation.isAuthorOfPublication | f0de2f21-778a-4cf2-860c-75dfc1f4a4fa | |
| relation.isAuthorOfPublication.latestForDiscovery | f0de2f21-778a-4cf2-860c-75dfc1f4a4fa |